AI Article Synopsis
- The study examined how well the HIV drug rilpivirine is transferred from mother to fetus using human placental tissues.
- The mean fetal transfer rate of rilpivirine was found to be 26%, indicating a significant amount reaches the fetus.
- The findings suggest that fetuses are likely exposed to rilpivirine when their mothers are treated with this medication.
Article Abstract
Placental transfers of the HIV nonnucleoside reverse transcriptase inhibitor rilpivirine were investigated in 8 term human cotyledons perfused with rilpivirine (400 ng/ml) in the maternal-to-fetal direction. The mean fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 15 to 90 min) was 26% ± 8% (mean ± standard deviation), and the clearance index (rilpivirine FTR/antipyrine FTR) was 61% ± 20%. This shows that rilpivirine crosses the placenta at a relatively high rate, suggesting that the fetus is exposed to the compound during treatment of the mother.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394829 | PMC |
| http://dx.doi.org/10.1128/AAC.00075-15 | DOI Listing |
Publication Analysis
Top Keywords
rilpivirine
5
placental transfer
4
transfer rilpivirine
4
rilpivirine vivo
4
vivo human
4
human cotyledon
4
cotyledon perfusion
4
perfusion model
4
model placental
4
placental transfers
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!